Kaltwasser J P, Schwarz-van de Sand W
Abteilung Hämatologie, Universität Frankfurt/Main.
Dtsch Med Wochenschr. 1989 Aug 4;114(31-32):1188-95. doi: 10.1055/s-2008-1066738.
Bio-availability and therapeutic efficacy of two oral ferrous preparations in the form of effervescent tablets (A and A*) were compared. In a randomly controlled trial, postabsorption rise of serum iron was compared intraindividually after oral intake of the effervescent tablets and of an optimally bio-available ferrous ascorbate standard solution (80.5 mg). Afterwards the therapeutic efficacy of both preparations (161 mg daily) was compared with a proprietary iron preparation (B: 150 mg daily) for three months. The trial was conducted on 24 male subjects (aged 20-38 years) who underwent weekly phlebotomies of 500 ml until exhaustion of body iron reserves and development of a mild iron-deficiency anaemia (standard phlebotomy protocol). Relative bioavailability, related to the standard iron solution, was 89% and 104%, respectively, for tablets A and A*. The rise in haemoglobin and ferritin during the three-months treatment was relatively the same for all three preparations: the average daily haemoglobin rise (means +/- SD) was 1.4 +/- 0.5 g/l (A), 1.5 +/- 0.4 g/l (A*) and 1.2 +/- 0.5 g/l (B), respectively, the differences not being statistically significant.
比较了两种泡腾片形式(A和A*)的口服亚铁制剂的生物利用度和治疗效果。在一项随机对照试验中,口服泡腾片和最佳生物利用度的亚铁抗坏血酸标准溶液(80.5毫克)后,对个体吸收后血清铁的升高进行了比较。之后,将两种制剂(每日161毫克)与一种专利铁制剂(B:每日150毫克)的治疗效果进行了三个月的比较。该试验对24名男性受试者(年龄20 - 38岁)进行,这些受试者每周进行500毫升的静脉放血,直至身体铁储备耗尽并发展为轻度缺铁性贫血(标准静脉放血方案)。与标准铁溶液相比,片剂A和A的相对生物利用度分别为89%和104%。在三个月的治疗期间,所有三种制剂血红蛋白和铁蛋白的升高相对相同:平均每日血红蛋白升高(均值±标准差)分别为1.4±0.5克/升(A)、1.5±0.4克/升(A)和1.2±0.5克/升(B),差异无统计学意义。